|
Realtime-Estimate
Cboe BZX
21:09:04 17.11.2026
|
Perf. 5 T | Veränd. 1. Jan. | ||
| 10.60 USD | -10.32% |
|
-39.90% | -38.74% |
| 16.11. | Regulatorischer Rückschlag für Summit Therapeutics, Aktie stürzt ab | |
| 16.11. | Summit-Aktien fallen, nachdem die US-FDA die Zulassung eines Lungenkrebsmedikaments ablehnt | RE |
ETFs investiert in Summit Therapeutics Inc.
| Name | % 1. Jan. | Gewichtung | Volumen | |
|---|---|---|---|---|
| +4.41% | 1.47% | 222 M€ | ||
| +12.93% | 1.21% | 1 191 M€ | ||
| +17.64% | 1.05% | 131 M€ | ||
| +18.53% | 0.99% | 10 676 M€ | ||
| +21.78% | 0.98% | 81 M€ | ||
| +18.55% | 0.97% | 35 M€ | ||
| +22.18% | 0.88% | 1 079 M€ | ||
| +22.11% | 0.88% | 78 M€ | ||
| +3.73% | 0.71% | 50 M€ | ||
| +21.62% | 0.61% | 58 M€ | ||
| -2.05% | 0.51% | 115 M€ | ||
| +4.47% | 0.24% | 608 M€ | ||
| +11.43% | 0.18% | 2 036 M€ | ||
| +22.15% | 0.14% | 9 953 M€ | ||
| +10.68% | 0.11% | 847 M€ | ||
| +10.90% | 0.07% | 5 739 M€ | ||
| +5.97% | 0.07% | 671 M€ | ||
| +13.72% | 0.05% | 15 185 M€ | ||
| +13.63% | 0.05% | 38 076 M€ | ||
| +4.50% | 0.04% | 10 846 M€ | ||
| +18.22% | 0.04% | 19 074 M€ | ||
| +12.59% | 0.04% | 2 126 M€ | ||
| +8.85% | 0.03% | 292 M€ | ||
| +18.63% | 0.03% | 3 718 M€ | ||
| +19.11% | 0.03% | 102 M€ | ||
| +12.83% | 0.03% | 272 M€ | ||
| +4.90% | 0.02% | 19 M€ | ||
| +5.67% | 0.02% | 15 312 M€ | ||
| +15.31% | 0.02% | 1 724 M€ | ||
| +6.10% | 0.01% | 21 M€ | ||
| -5.94% | 0.01% | 454 M€ | ||
| +14.89% | 0.01% | 16 084 M€ | ||
| -0.88% | 0.01% | 3 279 M€ | ||
| +9.93% | 0.01% | 6 184 M€ | ||
| -7.04% | 0.01% | 127 465 M€ | ||
| -6.97% | 0.01% | 45 759 M€ |
Beschäftigte
265
Sektor
Biotechnologie
- Börse
- Aktien
- A2QDFS Aktie
- ETFs Summit Therapeutics Inc.
Bitte wählen Sie Ihre Edition
Alle länderspezifischen Finanzinformationen
















